Cargando…
Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Ch...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172988/ https://www.ncbi.nlm.nih.gov/pubmed/34095173 http://dx.doi.org/10.3389/fmed.2021.663680 |